Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy (MoveDMD®)
A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy
Sponsor: Catabasis Pharmaceuticals
This PHASE1/PHASE2 trial investigates Muscular Dystrophy, Duchenne and is currently completed. Catabasis Pharmaceuticals leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Apr 2022 — Sep 2022 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 6 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Nov 2018 — Dec 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Catabasis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .